These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

490 related articles for article (PubMed ID: 30367208)

  • 21. Left Ventricular Mass Change After Anthracycline Chemotherapy.
    Jordan JH; Castellino SM; Meléndez GC; Klepin HD; Ellis LR; Lamar Z; Vasu S; Kitzman DW; Ntim WO; Brubaker PH; Reichek N; D'Agostino RB; Hundley WG
    Circ Heart Fail; 2018 Jul; 11(7):e004560. PubMed ID: 29991488
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Progressive 3-Month Increase in LV Myocardial ECV After Anthracycline-Based Chemotherapy.
    Meléndez GC; Jordan JH; D'Agostino RB; Vasu S; Hamilton CA; Hundley WG
    JACC Cardiovasc Imaging; 2017 Jun; 10(6):708-709. PubMed ID: 27544895
    [No Abstract]   [Full Text] [Related]  

  • 23. Longitudinal assessment of concurrent changes in left ventricular ejection fraction and left ventricular myocardial tissue characteristics after administration of cardiotoxic chemotherapies using T1-weighted and T2-weighted cardiovascular magnetic resonance.
    Jordan JH; D'Agostino RB; Hamilton CA; Vasu S; Hall ME; Kitzman DW; Thohan V; Lawrence JA; Ellis LR; Lash TL; Hundley WG
    Circ Cardiovasc Imaging; 2014 Nov; 7(6):872-9. PubMed ID: 25273568
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment.
    Ewer MS; Vooletich MT; Durand JB; Woods ML; Davis JR; Valero V; Lenihan DJ
    J Clin Oncol; 2005 Nov; 23(31):7820-6. PubMed ID: 16258084
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: a systematic review and meta-analysis.
    Kalam K; Marwick TH
    Eur J Cancer; 2013 Sep; 49(13):2900-9. PubMed ID: 23706982
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of prophylactic betablocker or ACE inhibitor on cardiac dysfunction & heart failure during anthracycline chemotherapy ± trastuzumab.
    Gujral DM; Lloyd G; Bhattacharyya S
    Breast; 2018 Feb; 37():64-71. PubMed ID: 29101824
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Correlations of the changes in bioptic findings with echocardiographic, clinical and laboratory parameters in patients with inflammatory cardiomyopathy.
    Krejci J; Hude P; Poloczkova H; Zampachova V; Stepanova R; Freiberger T; Nemcova E; Spinarova L
    Heart Vessels; 2016 Mar; 31(3):416-26. PubMed ID: 25539624
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relationship between regional left ventricular dysfunction and cancer-therapy-related cardiac dysfunction.
    Saijo Y; Kusunose K; Okushi Y; Yamada H; Toba H; Sata M
    Heart; 2020 Nov; 106(22):1752-1758. PubMed ID: 32209616
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cardioprotective Effects and Duration of Beta Blocker Therapy in Anthracycline-Treated Patients: A Systematic Review and Meta-analysis.
    Xu L; Long Y; Tang X; Zhang N
    Cardiovasc Toxicol; 2020 Feb; 20(1):11-19. PubMed ID: 31832905
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies are clinicians responding optimally?
    Yoon GJ; Telli ML; Kao DP; Matsuda KY; Carlson RW; Witteles RM
    J Am Coll Cardiol; 2010 Nov; 56(20):1644-50. PubMed ID: 21050974
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardioprotective role of β-blockers and angiotensin antagonists in early-onset anthracyclines-induced cardiotoxicity in adult patients: a systematic review and meta-analysis.
    Yun S; Vincelette ND; Abraham I
    Postgrad Med J; 2015 Nov; 91(1081):627-33. PubMed ID: 26399268
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimization of heart FailUre medical Treatment after hospital discharge according to left ventricUlaR Ejection fraction: the FUTURE survey.
    Cohen Solal A; Leurs I; Assyag P; Beauvais F; Clerson P; Contre C; Thebaut JF; Genoun M;
    Arch Cardiovasc Dis; 2012; 105(6-7):355-65. PubMed ID: 22800720
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Atorvastatin for Anthracycline-Associated Cardiac Dysfunction: The STOP-CA Randomized Clinical Trial.
    Neilan TG; Quinaglia T; Onoue T; Mahmood SS; Drobni ZD; Gilman HK; Smith A; Heemelaar JC; Brahmbhatt P; Ho JS; Sama S; Svoboda J; Neuberg DS; Abramson JS; Hochberg EP; Barnes JA; Armand P; Jacobsen ED; Jacobson CA; Kim AI; Soumerai JD; Han Y; Friedman RS; Lacasce AS; Ky B; Landsburg D; Nasta S; Kwong RY; Jerosch-Herold M; Redd RA; Hua L; Januzzi JL; Asnani A; Mousavi N; Scherrer-Crosbie M
    JAMA; 2023 Aug; 330(6):528-536. PubMed ID: 37552303
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention.
    Henriksen PA
    Heart; 2018 Jun; 104(12):971-977. PubMed ID: 29217634
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multicenter, Prospective, Randomized Controlled Trial of High-Sensitivity Cardiac Troponin I-Guided Combination Angiotensin Receptor Blockade and Beta-Blocker Therapy to Prevent Anthracycline Cardiotoxicity: The Cardiac CARE Trial.
    Henriksen PA; Hall P; MacPherson IR; Joshi SS; Singh T; Maclean M; Lewis S; Rodriguez A; Fletcher A; Everett RJ; Stavert H; Broom A; Eddie L; Primrose L; McVicars H; McKay P; Borley A; Rowntree C; Lord S; Collins G; Radford J; Guppy A; Williams MC; Japp A; Payne JR; Newby DE; Mills NL; Oikonomidou O; Lang NN
    Circulation; 2023 Nov; 148(21):1680-1690. PubMed ID: 37746692
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interventions for preventing cardiomyopathy due to anthracyclines: a Bayesian network meta-analysis.
    Abdel-Qadir H; Ong G; Fazelzad R; Amir E; Lee DS; Thavendiranathan P; Tomlinson G
    Ann Oncol; 2017 Mar; 28(3):628-633. PubMed ID: 28028033
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Abnormal Myocardial Strain Indices in Children Receiving Anthracycline Chemotherapy.
    Pignatelli RH; Ghazi P; Reddy SC; Thompson P; Cui Q; Castro J; Okcu MF; Jefferies JL
    Pediatr Cardiol; 2015 Dec; 36(8):1610-6. PubMed ID: 26049414
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    Laursen AH; Thune JJ; Hutchings M; Hasbak P; Kjaer A; Elming MB; Ripa RS
    Clin Physiol Funct Imaging; 2018 Mar; 38(2):176-185. PubMed ID: 28251781
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Meta-Analysis Comparing Usefulness of Beta Blockers to Preserve Left Ventricular Function During Anthracycline Therapy.
    Shah P; Garris R; Abboud R; Vasudev R; Patel H; Doshi R; Shamoon F; Bikkina M
    Am J Cardiol; 2019 Sep; 124(5):789-794. PubMed ID: 31307662
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Baseline Global Longitudinal Strain as a Predictor of Left Ventricular Dysfunction and Hospitalization for Heart Failure of Patients With Malignant Lymphoma After Anthracycline Therapy.
    Hatazawa K; Tanaka H; Nonaka A; Takada H; Soga F; Hatani Y; Matsuzoe H; Shimoura H; Ooka J; Sano H; Mochizuki Y; Matsumoto K; Hirata KI
    Circ J; 2018 Sep; 82(10):2566-2574. PubMed ID: 29984789
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.